Evidence map›Paper›PMID 31088744›Full record

ArticleVaccine2019

Patient report of herpes zoster pain: Incremental benefits of zoster vaccine live.

Katia J Bruxvoort, Anna S Liang, Rafael Harpaz, Lei Qian, Lina S Sy, Philip LaRussa, D Scott Schmid, Yi Luo, Harpreet Takhar, Hung Fu Tseng

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Extreme immunotherapy: emergency immunology to defeat pandemics.Molecular medicine (Cambridge, Mass.) · 2021
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Katia J BruxvoortDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Katia.Bruxvoort@kp.org.
Anna S LiangDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Shuhua.Liang@kp.org.
Rafael HarpazDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: rzh6@cdc.gov.
Lei QianDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Lei.X.Qian@kp.org.
Lina S SyDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Lina.S.Sy@kp.org.
Philip LaRussaDepartment of Pediatrics, College of Physicians and Surgeons, Columbia University, New York City, NY, United States. Electronic address: plarussa@columbia.edu.
D Scott SchmidDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, United States. Electronic address: dss1@cdc.gov.
Yi LuoDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Yi.X.Luo@kp.org.
Harpreet TakharDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Harpreet.S.Takhar@kp.org.
Hung Fu TsengDepartment of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States. Electronic address: Hung-Fu.X.Tseng@kp.org.
Kaiser Permanente · USCenters for Disease Control and Prevention · USColumbia University · US

Funding

Zoster Vaccine and Risk Factors of Zoster and Post-Herpetic NeuralgiaR01AI089930 · NIAID · KAISER FOUNDATION RESEARCH INSTITUTE · PI TSENG, HUNGFU · 2011 to 2015
$3.0M
NIAID NIH HHS R01 AI089930
6 · The paper itself

Abstract

introductionPain following herpes zoster (HZ) can persist for months and negatively impact quality of life. To evaluate the effect of zoster vaccine live (ZVL) on progression of pain following HZ, we conducted a prospective cohort study of HZ cases at Kaiser Permanente Southern California.

methodsZVL vaccinated and unvaccinated members aged ≥60 years with laboratory-confirmed HZ from January 18, 2012 to February 26, 2015 were followed up within 5 days of HZ diagnosis, and at 30, 60, and 90 days after diagnosis. Pain was assessed with the Zoster Brief Pain Inventory (ZBPI) on a 0-10 scale, using cut-points of ≥3, ≥5, and ≥7, with postherpetic neuralgia (PHN) defined as pain ≥3 at 90 days. Log binomial regression was used to estimate adjusted risk ratios (aRRs) and 95% confidence intervals (CIs) associated with pain, comparing vaccinated versus unvaccinated HZ patients.

resultsWe interviewed 509 vaccinated and 509 unvaccinated HZ patients. ZVL was associated with significantly lower risks of HZ-related pain at all time-points. The risk of PHN in vaccinated and unvaccinated patients, respectively, was 9.2% and 15.4% (aRR = 0.594, 95% CI: 0.413, 0.854); 2.0% and 4.8% of these patients reported pain ≥7 (aRR = 0.332, 95% CI: 0.153, 0.721). Irrespective of vaccination, the risk of PHN was lower in adults aged <70 years versus those ≥70 years and was similar or lower in females versus males.

conclusionWe used laboratory confirmation of HZ cases and patient survey to show that aside from preventing HZ, ZVL reduced HZ-related pain and prevented PHN among vaccine recipients who experienced HZ. Observational studies will be needed to evaluate long-term effectiveness of the new recombinant zoster vaccine and its benefits in protecting patients against PHN.

Indexed as

AgedFemaleHerpesvirus 3, HumanHerpes ZosterHerpes Zoster VaccineHumansMaleNeuralgia, PostherpeticPainProspective StudiesVaccinationHerpes Zoster VaccineHerpes zosterPostherpetic neuralgiaZoster vaccine

Identifiers

PMID31088744
PMCPMC6548453
OpenAlexW2944229289

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.